Q&A Dissecting Mental Illness Neuroscientist Barbara Lipska describes her experiences with symptoms of psychiatric illness caused by treatment for metastases in her brain. by Marci A. Landsmann Pembrolizumab Shows Further Promise for Melanoma In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected. by Brad Jones Forward Look Tackling Drug Resistance Researchers are studing new ways to keep treatments working longer. by Stephen Ornes Survivor Profile Living in the Here and Now A metastatic melanoma survivor is hopeful but realistic as new treatments become available. by Jenny Song Forward Look Cancer Immunotherapies Continue to Make Headway Drugs that harness the power of the immune system gain new approvals. by Alexandra Goho Survivor Profile Knowing Her Options When Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors. by Melissa Davlin First Person Keeping Sight of Hope A survivor keeps an eye on what's ahead after a rare cancer diagnosis. by Sue Russell Cancer Talk Considering the Term “Cancer Survivor” A study investigates how people who have been diagnosed with cancer feel about being called survivors. by Jen Tota McGivney Making Clinical Trials More Inclusive Broadening clinical trial eligibility criteria to include cancer patients who also have other health conditions could increase trial enrollment. by Ashley P. Taylor What Do Clinical Trial Endpoints Really Measure? A study investigates whether a commonly used clinical trial endpoint, progression-free survival, can be used to predict quality of life. by Jon Kelvey Shingles Risk Increased for Cancer Patients A new vaccine is safe for cancer patients but hard to find. by Nancy Averett More Posts